Diligence memo · auto-generated · as of July 2, 2026

Macrotope, Inc.

Macrotope, Inc. looks fair against its niche peers and is active on financing cadence.

SourceRaising on rhythm with a 1.3× step-up on the last round — momentum worth tracking before it's priced in.

Businessfiled

Macrotope, Inc. operates in Pharmaceuticals, based in PRINCETON.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Macrotope, Inc. has raised $900K in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $400K on 2025-05-27.

Most recent recorded round closed around 2025-05-27.

Valuation (modeled)modeled

Provath models Macrotope, Inc. at approximately $1.1M (range $224K–$2.7M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.73× the median modeled value of Pre-Seed Pharmaceuticals companies in 2025–2027 (19 peers) — value vs value, same stage and era. Within the normal band (73% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 18 months.

Last raise 13 mo ago; this sector typically re-raises about every 13 months.

Raising on or ahead of the sector's normal rhythm.

The last round stepped up 1.3× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 18% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 2% of those peers.

Closest niche peers: Fedora Pharmaceuticals Inc., PRG FlowChem, Inc., Adora Animal Health Corp, ABLi Therapeutics, Inc., NextEvo, Inc..

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.